Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J5RN
|
|||
| Former ID |
DNCL003087
|
|||
| Drug Name |
Armodafinil
|
|||
| Synonyms |
Nuvigil; 112111-43-0; (R)-Modafinil; (R)-(-)-Modafinil; CEP-10953; UNII-V63XWA605I; CRL 40982; CEP 10953; V63XWA605I; CHEMBL1201192; CHEBI:77590; 2-[(R)-(Diphenylmethyl)sulfinyl]acetamide; (-)-2-((R)-(Diphenylmethyl)sulfinyl)acetamide; (-)-2-[(r)-(diphenylmethyl)sulfinyl]acetamide; Armodafinil [USAN:INN]; armodafinilo; armodafinilum; l-Modafinil; Nuvigil (TN); (-)-(R)-modafinil; Armodafinil (USAN/INN); SCHEMBL34489; ZINC6156; ACE037; Armodafinil, > YFGHCGITMMYXAQ-LJQANCHMSA-N
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pediatric cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Approved | [1] | |
| Company |
Cephalon
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H15NO2S
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
|
|||
| InChI |
1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m1/s1
|
|||
| InChIKey |
YFGHCGITMMYXAQ-LJQANCHMSA-N
|
|||
| CAS Number |
CAS 112111-43-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
12014108, 14824208, 17397368, 24099806, 44823274, 57373290, 58107158, 80296077, 103771175, 125086994, 134357052, 135200656, 136236020, 137001280, 137239495, 137624470, 152258644, 160647479, 162189556, 164230581, 175267253, 175270376, 186007031, 223443057, 223454698, 223519240, 226420943, 249797709, 251964004
|
|||
| ChEBI ID |
CHEBI:77590
|
|||
| ADReCS Drug ID | BADD_D00167 | |||
| SuperDrug ATC ID |
N06BA07
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-1D (ADRA1D) | Target Info | Agonist | [2], [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | Adrenoceptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364. | |||
| REF 3 | US patent application no. 2014,0349,964, Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.